Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Lifitegrast Patent Expiration

Lifitegrast is Used for relieving symptoms of dry eye disease. It was first introduced by Bausch And Lomb Inc in its drug Xiidra on Jul 11, 2016. 3 different companies have introduced drugs containing Lifitegrast.


Lifitegrast Patents

Given below is the list of patents protecting Lifitegrast, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xiidra US10124000 Modulators of cellular adhesion Nov 05, 2024 Bausch And Lomb Inc
Xiidra US11058677 LFA-1 inhibitor formulations Dec 18, 2033 Bausch And Lomb Inc
Xiidra US7314938 Modulators of cellular adhesion Mar 10, 2025 Bausch And Lomb Inc
Xiidra US7745460 Modulators of cellular adhesion Nov 05, 2024 Bausch And Lomb Inc
Xiidra US7790743 Modulators of cellular adhesion Nov 05, 2024 Bausch And Lomb Inc
Xiidra US7928122 Modulators of cellular adhesion Nov 05, 2024 Bausch And Lomb Inc
Xiidra US8084047 Compositions and methods for treatment of eye disorders May 17, 2026 Bausch And Lomb Inc
Xiidra US8168655 Compositions and methods for treatment of eye disorders May 09, 2029 Bausch And Lomb Inc
Xiidra US8367701 Crystalline pharmaceutical and methods of preparation and use thereof Apr 15, 2029 Bausch And Lomb Inc
Xiidra US8592450 Compositions and methods for treatment of eye disorders May 17, 2026 Bausch And Lomb Inc
Xiidra US8927574 Crystalline pharmaceutical and methods of preparation and use thereof Nov 12, 2030 Bausch And Lomb Inc
Xiidra US9085553 LFA-1 inhibitor and methods of preparation and polymorph thereof Jul 25, 2033 Bausch And Lomb Inc
Xiidra US9216174 Modulators of cellular adhesion Nov 05, 2024 Bausch And Lomb Inc
Xiidra US9353088 Crystalline pharmaceutical and methods of preparation and use thereof Oct 21, 2030 Bausch And Lomb Inc
Xiidra US9447077 Crystalline pharmaceutical and methods of preparation and use thereof Apr 15, 2029 Bausch And Lomb Inc
Xiidra US9890141 Crystalline pharmaceutical and methods of preparation and use thereof Oct 21, 2030 Bausch And Lomb Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lifitegrast's patents.

Given below is the list recent legal activities going on the following patents of Lifitegrast.

Event Date Patent/Publication
Patent litigations
Withdrawal of Application for PTE 02 Jul, 2024 US8084047
Withdrawal of Application for PTE 02 Jul, 2024 US8168655
Withdrawal of Application for PTE 02 Jul, 2024 US8592450
Notice of Final Determination -Eligible 02 Jul, 2024 US7314938
Withdrawal of Application for PTE 02 Jul, 2024 US7790743
Payment of Maintenance Fee, 8th Year, Large Entity 21 Feb, 2024 US9447077
Paralegal TD Not accepted 14 Feb, 2024 US7314938
Email Notification 17 Jan, 2024 US7314938
Change in Power of Attorney (May Include Associate POA) 17 Jan, 2024 US7314938
Email Notification 05 Jan, 2024 US8592450



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Lifitegrast Generics

Several generic applications have been filed for Lifitegrast. The first generic version for Lifitegrast was by Micro Labs Ltd and was approved on Aug 4, 2023. And the latest generic version is by Eugia Pharma Specialities Ltd and was approved on Nov 7, 2023.

Given below is the list of companies who have filed for Lifitegrast generic.


1. EUGIA PHARMA

Eugia Pharma Specialities Ltd has filed for 1 generic for Lifitegrast. Given below are the details of the strengths of this generic introduced by Eugia Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
5% solution/drops Discontinued OPHTHALMIC N/A Nov 7, 2023


2. MICRO LABS

Micro Labs Ltd has filed for 1 generic for Lifitegrast. Given below are the details of the strengths of this generic introduced by Micro Labs.

Strength Dosage Form Availability Application Pathway TE code Launch Date
5% solution/drops Discontinued OPHTHALMIC N/A Aug 4, 2023